Showing results (181-190 of 369) with videos related to

Sort By:
Pageof 37
Cancer|June 15, 2013
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancerKaren A Autio, Neeta Pandit-Taskar, Jorge A Carrasquillo, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 24, 2004
Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostateDavid R Shaffer, Agnes Viale, Ryota Ishiwata, et al.
Cancer|April 28, 2004
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinomaMichael J Morris, Oren Smaletz, David Solit, et al.
Nature|August 5, 2005
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesisZhenbang Chen, Lloyd C Trotman, David Shaffer, et al.
The Journal of Urology|January 12, 2022
Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor ApalutamideAlexander Pan, Rachel E Reingold, Jimmy L Zhao, et al.
EJNMMI Research|May 19, 2015
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumorsNeeta Pandit-Taskar, Joseph A O'Donoghue, Chaitanya R Divgi, et al.
Journal of Immunotherapy and Precision Oncology|December 25, 2023
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate CancerDaniel Vargas P de Almeida, Justine M Anderson, Daniel C Danila, et al.
European Urology Oncology|June 18, 2019
Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled TrialsSungmin Woo, Chong Hyun Suh, James A Eastham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomyZohar A Dotan, Fernando J Bianco, Farhang Rabbani, et al.
The Lancet. Oncology|October 13, 2012
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective studyRobert W Ross, Matthew D Galsky, Howard I Scher, et al.
Pageof 37